XML 41 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Additional Information (Details)
$ in Thousands, SFr in Millions
1 Months Ended 9 Months Ended
Aug. 31, 2020
Sep. 30, 2021
USD ($)
Sep. 30, 2021
CHF (SFr)
Apr. 30, 2021
CHF (SFr)
Dec. 31, 2020
USD ($)
Commitments And Contingencies Disclosure [Line Items]          
Operating lease right-of-use asset   $ 68,450     $ 73,672
Lease Agreement          
Commitments And Contingencies Disclosure [Line Items]          
Operating lease right-of-use asset   0      
Lease liabilities   0      
Clinical and Commercial Supply of Drug Substance | Manufacturing Agreement | Lonza          
Commitments And Contingencies Disclosure [Line Items]          
Annual suite fees payment | SFr       SFr 150.0  
Revised estimated capital contribution | SFr       SFr 75.0  
Manufacturing agreement initial term 8 years        
Clinical and Commercial Supply of Drug Substance | Maximum | Manufacturing Agreement | Lonza          
Commitments And Contingencies Disclosure [Line Items]          
Manufacturing agreement term that can be extended 16 years        
Other Assets [Member] | Manufacturing Agreement          
Commitments And Contingencies Disclosure [Line Items]          
Manufacturing Agreement Expense   $ 38,700 SFr 35.0